VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Down 57.2% in July

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 48,730 shares, a drop of 57.2% from the June 30th total of 113,911 shares. Approximately 1.4% of the shares of the stock are sold short. Based on an average daily volume of 11,401,344 shares, the short-interest ratio is currently 0.0 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP purchased a new stake in VivoSim Labs, Inc. (NASDAQ:VIVS) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs as of its most recent filing with the Securities and Exchange Commission (SEC). 8.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

VivoSim Labs Trading Down 6.9%

Shares of NASDAQ:VIVS opened at $0.39 on Tuesday. The company has a market cap of $1.36 million, a price-to-earnings ratio of -0.07 and a beta of 1.40. VivoSim Labs has a 12 month low of $0.36 and a 12 month high of $5.30. The company has a 50-day moving average price of $1.02 and a 200 day moving average price of $1.52.

VivoSim Labs (NASDAQ:VIVS) last announced its earnings results on Tuesday, July 14th. The company reported ($2.21) EPS for the quarter. VivoSim Labs had a negative return on equity of 277.62% and a negative net margin of 10,567.17%.The company had revenue of $0.04 million during the quarter.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.